Maryland State Retirement & Pension System increased its stake in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 54.1% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 37,347 shares of the company’s stock after acquiring an additional 13,105 shares during the period. Maryland State Retirement & Pension System’s holdings in Alkermes were worth $1,513,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the business. Root Financial Partners LLC acquired a new stake in shares of Alkermes during the third quarter worth approximately $25,000. Ameritas Advisory Services LLC bought a new position in Alkermes during the 2nd quarter valued at $39,000. Versant Capital Management Inc boosted its stake in Alkermes by 33.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after acquiring an additional 366 shares during the last quarter. Harbor Investment Advisory LLC bought a new position in Alkermes during the 2nd quarter valued at $82,000. Finally, C M Bidwell & Associates Ltd. acquired a new position in Alkermes during the 2nd quarter worth $104,000. 95.21% of the stock is currently owned by institutional investors and hedge funds.
Alkermes Stock Performance
ALKS opened at $47.03 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.42 and a quick ratio of 2.02. The company has a market capitalization of $7.90 billion, a price-to-earnings ratio of -2,350.32 and a beta of 0.32. The business has a 50 day moving average price of $43.67 and a two-hundred day moving average price of $41.13. Alkermes plc has a 1-year low of $27.00 and a 1-year high of $55.67.
Alkermes (NASDAQ:ALKS – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17. The business had revenue of $480.13 million for the quarter, compared to the consensus estimate of $463.48 million. Alkermes had a negative net margin of 0.02% and a positive return on equity of 0.40%. The business’s revenue for the quarter was up 21.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.49 EPS. Research analysts predict that Alkermes plc will post -0.52 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, EVP David Gaffin sold 2,035 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total transaction of $93,955.95. Following the completion of the sale, the executive vice president owned 219,353 shares in the company, valued at approximately $10,127,528.01. This represents a 0.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total value of $422,910.00. Following the sale, the executive vice president directly owned 65,389 shares of the company’s stock, valued at approximately $3,072,629.11. This represents a 12.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 15,103 shares of company stock valued at $697,973 in the last quarter. Insiders own 4.59% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on ALKS shares. Piper Sandler reissued an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. JPMorgan Chase & Co. upped their target price on shares of Alkermes from $60.00 to $61.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Mizuho raised shares of Alkermes to a “strong-buy” rating in a research report on Wednesday, September 16th. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 price target on shares of Alkermes in a research note on Monday, September 21st. Finally, Robert W. Baird set a $61.00 price target on Alkermes in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.73.
View Our Latest Stock Report on Alkermes
About Alkermes
Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.
See Also
- Five stocks we like better than Alkermes
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
